Hims & Hers Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonna Kim from TD Cowen maintained a Hold rating on the stock and has a $43.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonna Kim has given his Hold rating due to a combination of factors impacting Hims & Hers Health’s outlook. Despite the anticipation of a positive earnings surprise for the second quarter of 2025, there are signs of slowing growth trends. This deceleration is evident in the sequential decline in year-over-year sales growth, which could prompt management to maintain their full-year guidance.
Additionally, the company faces challenging comparisons in the latter half of 2025, following significant sales growth in the previous year. There is also uncertainty surrounding compounded GLP-1s, which adds to the cautious stance. While international expansion presents a potential growth opportunity, the muted growth in web traffic suggests limited momentum in core business segments outside of weight loss.
According to TipRanks, Kim is a 4-star analyst with an average return of 19.5% and a 42.86% success rate. Kim covers the Consumer Cyclical sector, focusing on stocks such as Gap Inc, American Eagle, and Victoria’s Secret.
In another report released on July 17, Truist Financial also maintained a Hold rating on the stock with a $48.00 price target.